The size of the Middle East & Africa Radioimmunoassay Market was worth USD 36.72 million in 2022. It is further estimated to be growing at a CAGR of 3.18% and values USD 42.94 million by 2027.
The radioimmunoassay technique works on the principle of binding the assay. The binder is an antibody, which binds to the antigen, and the amount of antigen complex is measured by radioactivity. The radioimmunoassay has acquired significant importance in the field of medical diagnostics due to certain factors such as precision, accuracy, specificity of results, and sensitivity. However, the precision and sensitivity of the assay depend mainly on the quality of the antigens and antibodies collected and on the choice of separation techniques used. Therefore, radioimmunoassay kits are becoming increasingly popular as a vitro assay procedure in research institutes, diagnostic laboratories, pharmaceutical companies, the food and safety industry, and other healthcare establishments.
The wide applications of the radioimmunoassay technique, such as the radioimmunoassay to measure progesterone in cow's milk, early detection of cancer, autoimmune diseases, degenerative disorder, and drug reactivity, among others, are expected to fuel the demand for radioimmunoassay kits, which is anticipated to drive the MEA radioimmunoassay market in the upcoming years.
Growing research and development in the field of radioimmunoassay has given rise to newer products such as the immunoradiometric assay (IRMA), which is used with radiolabeled molecules and radioallergosorbent test (RAST), which is helpful to detect the causative allergen for a suspected allergy such as dust, pollen, medicine, and food substances, etc. Furthermore, with continuous study and evolution in the healthcare sector with an ever-changing list of diseases and allergens, the demand for radioimmunoassay is said to grow during the forecast period.
The presence of alternative methods that can be used to separate or identify or detect biomolecules will challenge the growth of the MEA radioimmunoassay market. In addition, the high cost of these kits can be a burden, and due to lack of funds and poor healthcare infrastructure in certain parts of Africa, the demand for radioimmunoassay can be affected, which is expected to restraint the overall market in the MEA region.
This research report on the Middle East and Africa radioimmunoassay market has been segmented and sub-segmented into the following categories:
By End User:
Based on the region, the major countries in the region are UAE, Saudi Arabia, Qatar, Egypt, and South Africa. The region is the smallest market globally, with a growth rate that is also below average. The Middle East and Africa market is said to be dominated by the GCC countries such as the kingdom of Saudi Arabia, United Arab Emirates, Qatar, and Oman, etc., attributed to the advanced healthcare infrastructure, availability and widespread adoption of latest diagnostic technologies, large patient population, increased demand for hi-grade and accurate tests, availability of public and private funds for research sectors. The region is also home to many key market players with a manufacturing base for easy distribution of the products.
Meanwhile, the African and Sun-Saharan region is also analyzed to grow at a steady growth rate during the forecasted period, owing to main factors such as increasing incidence of cancer and allergies, increase in medical tourism, an increasing number of laboratories and medical centers, awareness about various disease and the growth of in-vitro diagnostics procedures in these countries is estimated to drive the development of the MEA radioimmunoassay market during the forecast period.
KEY MARKET PLAYERS:
Companies playing a promising role in the Middle East & Africa radioimmunoassay market profiled in this report are DIAsource Immunoassays SA, Beckman Coulter, IBL International, PerkinElmer, DRG International, MP Biomedicals LLC, Cisbio, Euro Diagnostica AB, DiaSorin S.p. A, EMD Millipore, Izotop, Berthold Technologies GmbH & Co. KG and Stratec Biomedical AG.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org